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ABSTRACT
Vitamin D has been known as a vitamin for bone health and mineral 
homeostasis. However, since the discovery of vitamin D receptor (VDR) in 
various types of cell, that statement has changed. Immune cells are known to 
express VDR and enzyme 1α-hydroxylase that could convert vitamin D into its 
active form, 1.25 dihydroxyvitamin D. In immune cells, vitamin D works as 
an immunomodulator which affects various levels of immune response. The 
net effects of vitamin D are increasing mucosal immunity, but dampening the 
adaptive immune system. Vitamin D deficiency is commonly found in people 
with diabetes mellitus (DM) and obesity. It is also associated with increased 
insulin resistance and poor glucose control. This review will explain how 
vitamin D as immunomodulator dampens insulin resistance. In immune cells 
from subjects with insulin resistance, administration of vitamin D could reduce 
the expression of pro-inflammatory cytokines through the NF-κB and MAPK 
pathways, thus the levels of pro-inflammatory cytokines such as TNFα, IL-1β, 
and IL-6 are decreased. The same thing happens in preadipocytes and mature 
adipocytes cells. In these cells, vitamin D suppresses the expression of pro-
inflammatory mediators such as IL-6 and MCP-1. Although in the invitro studies, 
the administration of vitamin D showed a promising effect in modulating the 
immune system, the clinical effect of vitamin D supplementation in reducing 
insulin resistance in individuals with type 2 DM (T2DM) and prediabetes is still 
inconclusive
ABSTRAK
Vitamin D dikenal sebagai vitamin untuk kesehatan tulang dan homeostasis 
mineral. Namun, sejak ditemukannya reseptor vitamin D (VDR) di berbagai 
jenis sel, pernyataan itu telah berubah. Sel kekebalan dikenal untuk 
mengekspresikan VDR dan enzim 1α-hidroksilase yang dapat mengubah 
vitamin D menjadi bentuk aktifnya, 1,25 dihydroxy vitamin D. Dalam sel 
kekebalan, vitamin D bekerja sebagai imunomodulator yang memengaruhi 
berbagai tingkat respons imun. Efek vitamin D itu sendiri adalah meningkatkan 
kekebalan mukosa, tetapi mengurangi system kekebalan adaptif. Kekurangan 
vitamin D umumnya ditemukan pada penderita diabetes melitus(DM) dan 
obesitas. Hal ini terkait dengan peningkatan resistensi insulin dan control 
glukosa yang buruk. Ulasan ini akan menjelaskan bagaimana vitamin D 
sebagai imuno modulator mengurangi resistensi insulin. Dalam sel imun dari 
subyek dengan resistensi insulin, pemberian vitamin D dapat mengurangi 
ekspresi sitokin proinflamasi melalui jalur NF-κB dan MAPK, sehingga tingkat 
sitokin proinflamasi seperti TNFα, IL-1β, dan IL-6 menurun. Hal yang sama 
terjadi dengan sel preadiposit dan adiposit matang. Dalam sel ini, vitamin D 
menekan ekspresi mediator proinflamasi seperti IL-6 dan MCP-1. Meskipun 
dalam penelitian invitro, pemberian vitamin D menunjukkan efek yang 
menjanjikan dalam memodulasi system kekebalan, efek klinis suplementasi 
vitamin D dalam mengurangi resistensi insulin padapasien DM tipe 2 dan 
pradiabetes masih belum dapat disimpulkan.
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INTRODUCTION
Since long ago, vitamin D has been 
known as a vitamin for bone health and 
mineral homeostasis. Vitamin D could 
enhance the absorption of calcium and 
phosphate in the intestine, stimulate 
the osteoclasts differentiation, enhance 
calcium reabsorption from bones and 
induce matrix mineralization.1 However, 
in the last decades, the role of vitamin 
D affecting human health changed 
rapidly, especially after the discovery of 
vitamin D receptor (VDR) and enzyme 
1α-hydroxylase (CYP27B1) in several 
cell types that not related to mineral 
and bone metabolisms such as intestine, 
pancreas, prostate and immune cells.2 
This indicates that vitamin D has a 
broader role than is currently known, 
including in the field of immunology.
In immunology, the active form of 
vitamin D, 1.25-dihydroxyvitamin D 
is able to influence the proliferation 
and differentiation of immune cells.3 
Moreover, vitamin D could modulate 
the innate and adaptive immune 
response. Some studies revealed that 
vitamin D deficiency was associated with 
autoimmune diseases, cardiovascular 
disorders, cancers, and infections.1-3
In metabolic disease, vitamin D 
deficiency is associated with metabolic 
disorders such as obesity, insulin 
resistance (IR), and type 2 diabetes 
mellitus (T2DM). Vanlint4 revealed 
that obese people tend to have low 
vitamin D levels. In patients with T2DM 
and ingeneral population, low level 
of 25-hydroxyvitamin D is associated 
with higher fasting blood glucose level, 
higher HbA1c, increased HOMA-IR and 
increased risk of metabolic syndrome.5-6 
Survey conducted by NHANES III in 
6228 people showed that the level of 
25-hydroxyvitamin D more than 81 
nmol/L was a protective factor against 
the development of T2DM.7
In this paper, the author would 
like to discuss the mechanism of 
vitamin D in the immune system. How 
vitamin D suppresses the secretion of 
proinflammatory mediators released 
by immune cells and adipose cells, and 
whether vitamin D supplementation can 
reduce insulin resistance in prediabetic 
and T2DM patients will be discussed.
DISCUSSION
Vitamin D
Source, metabolism, and regulation
There are two main forms of vitamin 
D, vitamin D2 (ergocalciferol) and vitamin 
D3 (cholecalciferol). Ergocalciferol is 
synthesized by plants in the presence 
of UV light, whereas cholecalciferol is 
endogenously produced by human body 
and it is also found in some dietary 
sources. The biological function of both 
forms of vitamin D is carried out by same 
active form, 1.25 dihydroxyvitamin D.8 
This paper would focus on vitamin D3 
since it is normally found in human body.
Vitamin D3 could be obtained from 
3 potential sources, which are nutrition, 
UVB-dependent endogenous production, 
and supplementation.1 In human, 
vitamin D is synthesized in the skin 
after exposed to UVB, while nutrition 
contributes only small amounts of 
vitamin D.1 There are very few natural 
food products which contain vitamin D3, 
including fatty fish (salmon, sardines, 
mackerel, cod liver oil) and some types 
of fungi.1 Some countries implement 
vitamin D fortification policy by adding 
vitamin D to various food products such 
as dairy products.9 Thus, vitamin D intake 
is very dependent on nutritional intake 
and fortification policy in the country.9 
In addition, vitamin D levels are also 
associated with endogenous production 
of vitamin D which is influenced by 
genetic factors, locations, seasons, skin 
pigmentation, and lifestyle such as using 
sunscreen and wearing full-covered 
clothes.9
FIGURE 1 shows the metabolism 
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of vitamin D3. First, in the skin, 
7-dehydrocholesterol (provitamin D3) 
is converted to previtamin D3 when 
it is exposed to UVB with 290-312 nm 
wavelength and then it is immediately 
converted to vitamin D3.
10 Cholecalciferol 
is biologically inactive and bound to 
vitamin D binding protein (DBP) or 
albumin.10 Cholecalciferol which is 
bound to DBP enters the circulation 
and is carried to the liver. In the liver, 
enzyme CYP2R1 (cytochrome P450 
vitamin D 25-hydroxylase) and CYP27A1 
will hydrolyze cholecalciferol into 
25-hydroxyvitamin D which represents 
the main metabolite of vitamin D and the 
most trusted parameter for determining 
vitamin D status in human.10
Almost all DBP-bound25 
hydroxyvitamin D is filtered in the 
kidneys and reabsorbed by the proximal 
renal tubules. In the kidney, megalin, 
and cubitin, the member of the LDL 
receptor superfamily, endocytosis 25 
hydroxyvitamin D. In this tubules, 25 
hydroxyvitamin D is hydroxylated by 
enzyme 1α-hydroxylase (CYP27B1) 
to become its active form, 1.25 
dihydroxyvitamin D.10
Converting 25 hydroxyvitamin 
D to an active metabolite, 1.25 
dihydroxyvitamin D by the enzyme 
1α-hydroxylase in kidneyis under the 
regulation of parathyroid hormone 
(PTH) and fibroblast growth factor 23 
(FGF-23). PTH induces the transcription 
of 1α-hydroxylasegene and nuclear 
receptor 4A2 as a transcription factor of 
1α-hydroxylase.11 Low levels of calcium 
and phosphate will also increase the 
activity of 1α-hydroxylase.11 In contrast, 
an increasedof 1.25 dihydroxyvitamin 
D level would suppress PTH production 
at the transcription level.11 Increased 
1.25 dihydroxyvitamin D leveland FGF-
23 also inhibit enzyme 1α-hydroxylase 
and stimulateenzyme 24-hydroxylase 
(CYP24A1) which converts 1.25 
dihydroxyvitamin D to an inactive and 
water-soluble form, thus it could be 
excreted.10
FIGURE 1. Synthesis, metabolism, and regulation 
of vitamin D. DBP: vitamin D binding 
protein; PTH: parathyroid hormone, FGF-
23: fibroblast growth factor – 23
J Med Sci, Volume 52, Number 2, 2020 April:
Various types of immune cells, 
such as monocytes, macrophages, 
dendritic cells, T and B cells also 
express theenzyme 1α-hydroxylase.
Therefore, they could convert 25 
hydroxyvitamin D to its active form, 1.25 
dihydroxyvitamin D in the paracrine 
or autocrine environment.12 Moreover, 
macrophages and dendritic cells, do 
not have negative feedback mechanism 
such as in the kidney, so these cells 
could produce 1.25 dihydroxyvitamin 
D in high concentration needed for 
immunomodulation.12
Vitamin D binding protein (DBP) and 
vitamin D receptor (VDR)
In order to reach the target cells, 25 
hydroxyvitamin D is bound to the vitamin 
D binding protein (DBP). DBP is encoded 
by the GC gene which has a function 
as a specific transporter for vitamin 
D metabolites and plays an important 
role in endocytosis of vitamin D.13 DBP 
is a glycoprotein that synthesized and 
secreted by the liver. DBP forms a vitamin 
D complex to maintain the availability of 
vitamin D in the target tissues.14
Vitamin D signaling occurs when 1.25 
dihydroxyvitamin D binds to a vitamin 
D receptor (VDR) located either in the 
cytoplasm or in the nucleus.15 VDR is a 
transcription activator or suppressor for 
several genes.15 The VDR gene is located 
on chromosome 12q13.1. It consists of 
14 exons and has a promoter region that 
could induce the transcription of specific 
genes in some tissues. VDR is expressed in 
more than 38 types of tissue and plays an 
important role in controlling vital genes 
such as bone metabolism and disruption 
of these receptor causes oxidative stress, 
development of chronic diseases and 
inflammation.15 After binding to its 
natural ligand, 1.25 dihydroxyvitamin D; 
VDR forms a heterodimer with retinoid 
X receptor (RXR), then it undergoes 
conformational changes and causes 
the complex to interact with genes that 
encode enzymes and proteins needed for 
remodeling and transcription activities.15
Role of vitamin D in suppressing 
inflammatory responses in insulin 
resistance
Mechanism of insulin resistance
Insulin resistance (IR) is a condition 
characterized by insulin-sensitive 
tissues, such as skeletal muscle, liver, and 
adipose tissues become less sensitive to 
insulin.16 The pathogenesis of IR is often 
associated with low-grade inflammatory 
condition.17 In patients with IR, there is an 
increase of proinflammatory cytokines 
such as TNFα, IL-1β, and IL-6 which are 
secreted by immune cells and adipose 
cells. These proinflammatory cytokines 
could phosphorylate the inhibitory 
kappa B kinase beta (IκKβ), a serine 
kinase I protein from the NF-κB pathway 
and Jun N terminal kinase I (JNK1) 
from the JNK/AP-1 pathway. Activated 
those pathways eventually could 
inactivate insulin receptor substrate 1 
(IRS1) in the insulin signal transduction 
pathway (FIGURE 2).18 Moreover, it is 
revealed that the proportion of Th1 
and Th17 which secrete interferon 
γ (IFN γ) and interleukin 17 (IL-17) 
respectivelyincreased in IR.19 Increased 
levels of IFNγ and IL-17 will activate 
more macrophages, thus it could worsen 
the low-grade inflammation condition.19
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FIGURE 2. Mechanism of insulin resistance related to 
inflammatory cytokines in insulin sensitive 
tissues
Role of vitamin D in immune system
Vitamin D affects the immune 
system at various levels with the end 
effect isincreasing mucosal immunity, 
but suppressing the adaptive immune 
response.13,20 At mucosal membranes, 
vitamin D enhance chemotaxis and 
phagocytosis activities of innate immune 
cells. Futhermore, a complex of 1.25 
dihydroxy vitamin D, VDR, and RXR 
could directly stimulate the transcription 
of anti microbial peptides such as 
defensins-β2 (DEFB) and cathelicidin 
(HCAP) in macrophages.12 Antimicrobial 
peptide would eliminate enveloped 
virus,  bacteria, and fungi by disturbing 
the structure of their cell membranes.12 
Vitamin D could suppress adaptive 
immune system by altering the function 
of dendritic cells to be more tolerogenic 
that characterized by decreased 
expression of costimulatory molecules 
(CD80/86), MHC class II, and decreased 
IL-12 secretion, while IL-10 secretion 
increases.11,12
The previous study revealed that 
T and B lymphocytes express VDR and 
enzyme 1α-hydroxylase.1 Expression of 
VDR in these cells is very low when cells 
are resting, but when activated, T and 
B lymphocytes significantly increase 
VDR expression, which causes vitamin 
D might influence cell differentiation 
and proliferation. Vitamin D exposure 
alsoinduces adaptive immune response 
to be more tolerogenic and affects 
various types of T lymphocytes. 1.25 
dihydroxyvitamin D suppresses 
proliferation, differentiation effector T 
cells and modulates cytokines production 
from Th1 dan Th17 cells. On the other 
hands, vitamin D promotes proliferation 
and differentiation of Treg and Th2 
cells.13
Vitamin D reduceslow-grade inflammation 
in insulin resistance
Low-grade inflammation is one 
of the causes of insulin resistance 
which increases the risk of T2DM. In 
LPS-stimulated macrophages, 1.25 
dihydroxyvitamin D could increase IκB α, 
an NF-κB inhibitor, by increasing mRNA 
stability and decreasing phosphorylation 
of IκB α.21 Increased level of IκB α would 
decrease nuclear translocation ofNF-
κB.21 In addition, other studies mentioned 
that 1.25 dihydroxyvitamin D interacted 
with IκKB, a protein kinase, soNF-κB 
activation is inhibited.22 By inhibiting 
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phosphorylation IκKB, the activity 
of the IκK enzyme complex which 
phosphorylates IκBα decreases, thus this 
mechanism could inhibit degradation of 
IκB α.22
According to FIGURE 3, vitamin 
D  could decrease the inflammatory 
response of innate cells such as TNF α, IL-
6, IL-1, IL-8, COX-2, intercellular adhesion 
molecule (ICAM)1, and molecule B7-1 in 
macrophages.10 Other studies revealed 
that 1.25 dihydroxyvitamin D and 
25 hydroxyvitamin D could reduce 
the production of TNF α and IL-6 in 
LPS-induced macrophages through 
the MAPK pathway.23 Moreover, 1.25 
dihydroxyvitamin D also inhibits the 
release of IL-12, IL-2, IFN γ, and TNF 
α which play roles in pancreatic β cell 
dysfunction.
Vitamin D modulates T lymphocytes 
function by decreasing the development 
of Th1 and Th17 cells, but increasing 
the proliferation of Th2 and Treg cells. 
This modulating effect can protect target 
tissues such as pancreatic β cells, thereby 
reducing IR.24 Moreover, treatment of 
vitamin D could reduce the number 
of Th1 cells in secondary lymphoid 
organs. In another study, treatment of 
vitamin D inhibited the transcription of 
IL17 gene by suppressing the nuclear 
factor for activates T cells (NFAT), 
inhibiting histone deacetylation, and 
blockingrunt-relates transcription factor 
1 (Runx1).25 Besides inhibiting effector T 
cells activation, vitamin D could induce 
apoptosis in those cells through FAS and 
TIM3 pathways.25 Vitamin D induces the 
pro-apoptotic gene that encodes caspase 
8-associated protein and inhibits cellular 
inhibitors of apoptosis protein 2 (cIAP-
2).25 Vitamin D also induces apoptosis by 
stimulating Treg cells to express galectin, 
a protein that induces effector T cell 
apoptosis through TIM3 receptor. In Treg 
cells and Tr1 cells, 1.25 dihydroxyvitamin 
D increases the transcription of Foxp3+ 
gene, CTLA-4 protein expression, and the 
production of IL-10.25
FIGURE 3. Vitamin D suppresses pro-inflammatory 
and enhances anti-inflammatory 
responses in T2DM
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Role of vitamin D in adipose tissue
IR is closely related to obesity. In 
obesity, hypertrophy and hyperplasia 
of adipocytescause disruption of 
blood flow that makes tissue becomes 
hypoxic, inflammation, and infiltrated 
by macrophages.26 This disturbance 
is characterized by an increased 
level of IL-6, IL-8, resistin, TNF α, and 
monocytes chemoattractant (MCP-
1) and also changed in adiponectin 
secretion.27 Previous study revealed 
that adipocytes expressed VDR and 
enzyme 1α-hydroxylase, therefore 
adipocytes could metabolize 25 
hydroxyvitamin D into its active form, 
1.25 dihydroxyvitamin D and utilize it.27 
In adipocytes, activation of NF-κB begins 
with the IκB α protein degradation that 
permits the NF-κB subunit migratesto 
the nucleus and inducesthe transcription 
of the proinflammatory genes.26 The 
study conducted by Gao et al.28 stated 
that 1.25 dihydroxyvitamin D could 
increaseIκB α protein in human pre-
adipocytes and treatment with 1.25 
dihydroxyvitaminvitamin D decreased 
IL-6 and MCP-1 secretion from 
human preadipocytes and decreased 
preadipocyte-induced macrophage 
activation. The latest study stated that 
1.25 dihydroxyvitamin D could also 
inhibit the degradation of IκB α protein 
and decrease the expression of p65 
NF-κB in human adult adipocytes.29 
In addition, Mutt et al.30 revealed that 
1.25 dihydroxyvitamin D could inhibit 
the translocation of p65 NF-κB to the 
adipocyte nucleus. Therefore, it could 
reduce the secretion of proinflammatory 
cytokines.
Research in obesity revealed that 
there was a relationship between obesity 
and vitamin D deficiency. Obese people 
tend to have a low vitamin D level.4 
Decreased vitamin D levels in obese 
people could be caused by low vitamin D 
intake, decreased vitamin D synthesis in 
the skin, decreased vitamin D absorption 
in the intestine, and changed vitamin D 
metabolism.4
Effects of vitamin D supplementation 
in insulin resistance
Although vitamin D deficiency is 
common in people with T2DM and obesity, 
the effects of vitamin D supplementation 
in reducing insulin resistance and 
improving glucose control in both T2DM 
and pre-diabetes are still controversial. 
In a systematic review study in patients 
with T2DM, it was found that vitamin D 
supplementation could reduce HbA1c 
and fasting blood glucose only in patients 
with T2DM who had vitamin D deficiency. 
However, vitamin D supplementation 
did not affect patients with T2DM with 
insufficient and sufficient vitamin D 
levels.31 From a study conducted by He 
et al.32 it was concluded that the effect 
of vitamin D supplementation varied 
depending on the initial serum vitamin 
D level and patient’s body mass index. 
Furthermore, randomized clinical trial 
study from Iran revealed that 12 week-
oral vitamin D did not affect insulin 
sensitivity in pre-diabetes patients.33
It has been described that vitamin D 
deficiency had a potential role in changes 
of glucose homeostasis and insulin 
secretion either in vitro or in vivo study. 
However, effect of vitamin D intervention 
in improving insulin sensitivity is still 
inconclusive. Many factors have been 
found influence the results, such as age, 
race, dietary habits, level of activity, and 
obesity. Obesity influenced the effect 
of vitamin D supplementation because 
vitamin D is a fat-soluble compound so 
it will be stored in adipose cells. Thus, 
it needs large-scale randomized trials 
with longer duration to analyze the 
advantageous effects of vitamin D.
CONCLUSION
In insulin resistance, vitamin 
D can suppress the expression of 
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proinflammatory cytokines through 
the NF-κBand MAPK pathways in the 
immune cells and adipocytes, hence the 
levels of proinflammatory cytokines 
such as TNFα, IL-1β, and IL-6 could 
bereduced. Vitamin D could inhibit 
the degradation of protein IκB α and 
inhibit phosphorylation of enzymes 
IκKβ, thus makes the translocation 
of protein p65 NF-κB to the nucleus 
decreases. Vitamin D also suppresses 
the activation and proliferation of 
effector T cells by inhibiting NFAT, 
Runx1, and histone deacetylation. In 
addition, vitamin D induces apoptosis 
in effector T cell through TIM3 and 
FAS pathways, and vitamin D could 
increase  the transcription of the Foxp3 
gene in regulatory T cells. Although 
in an in vitro study,  administration of 
vitamin D showed the promising effect 
in modulating the immune system, the 
effect of vitamin D supplementation 
in reducing insulin resistance in 
individuals with T2DM and pre-diabetes 
is still inconclusive.
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